Home Newsfeeds Keros Therapeutics Q4 EPS $(1.09) Beats $(1.10) Estimate

Keros Therapeutics Q4 EPS $(1.09) Beats $(1.10) Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share

byHappy Mohamed

March 3, 2023

1 minute read

Wells Fargo Maintains Overweight on Marvell Tech, Lowers Price Target to $54

By Benzinga Newsdesk

December 2, 9:32 AM

Wells Fargo analyst Gary Mobley maintains Marvell Tech (NASDAQ:MRVL) with a Overweight and lowers the price target from $58 to $54.

MRVL

News

Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher

By Henry Khederian

February 8, 12:48 PM

Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development.

FHTX

Masimo W1 Medical Watch Receives FDA 510(k) Clearance For Over-The-Counter And Prescription Use

By Benzinga Newsdesk

November 17, 5:25 PM

Masimo (NASDAQ:MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx). Masimo W1 is the first FDA-cleared watch to provide

MASI

This Weed Company Reports 48% YoY Revenue Decline In Q2, Delists From CBOE

By Nina Zdinjak

August 16, 9:09 AM

Cannabis company Halo Collective Inc. (NEO: HALO) (OTCPK: HCANF) (FSE: A9K0) reported Tuesday its financial results for the second quarter of 2023 revealing revenue of $3.57 million down by 48.1% lower than in the same period of 2022.

HCANF

Keros Therapeutics Q4 EPS $(1.09) Beats $(1.10) Estimate

Related Posts

Wells Fargo Maintains Overweight on Marvell Tech, Lowers Price Target to $54

Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher

Masimo W1 Medical Watch Receives FDA 510(k) Clearance For Over-The-Counter And Prescription Use

This Weed Company Reports 48% YoY Revenue Decline In Q2, Delists From CBOE